



**Calendar Year 2024  
Part D Improper Payment Measure**

---

**SUBMISSION INSTRUCTIONS**

**January 23, 2026**

**Submission Deadline:  
April 17, 2026 by 11:59 p.m., Pacific Time (PT)**

## TABLE OF CONTENTS

<b>Introduction .....</b>	<b>1</b>
<b>Records Maintenance Expectations and Requirements.....</b>	<b>1</b>
<b>Part D IPM Overview .....</b>	<b>2</b>
Part D Sponsor Responsibilities .....	2
Part D IPM Timeline .....	3
<b>Part D IPM Supporting Documentation .....</b>	<b>4</b>
Best Practices for Supporting Documentation .....	5
Prescription Record Hardcopy (Mail/Retail Pharmacies) .....	6
Medication Order (LTC Pharmacies).....	13
Claim Detail File.....	21
<b>Identifying Selected PDE Records.....</b>	<b>23</b>
<b>Submission Process .....</b>	<b>26</b>
Supporting Documentation Submission .....	26
File Consolidation, Upload, and Verification.....	27
Verification Checks and Resubmission .....	33
<b>Best Practices .....</b>	<b>34</b>
<b>Contact Information .....</b>	<b>35</b>
Policy Questions .....	35
Part D IPM Submission Process Questions.....	35
HPMS Help Desk .....	36
CMS Meeting Request.....	36
<b>Appendix A. CMS Policy Regarding Adjusted Claims .....</b>	<b>37</b>
<b>Appendix B. PDE Layout .....</b>	<b>38</b>

## LIST OF EXHIBITS

Figure 1: Examples of Acceptable Prescription Record Hardcopies .....	7
Figure 2: Example of Micro-Tag .....	8
Figure 3: Examples of Acceptable Prescription Record Hardcopy Documentation .....	8
Figure 4: Example of Unacceptable Documentation – Prescription History .....	9
Figure 5: Example of Unacceptable Documentation – Pharmacy Attestation.....	10
Figure 6: Example of Unacceptable Documentation – Pharmacy Transaction File .....	10
Figure 7: Example of Unacceptable Documentation – Pharmacy Drug Utilization Review (DUR) Report .....	11

Figure 8: Example of Unacceptable Documentation – Patient Pickup Signature Log ...	11
Figure 9: Example of Unacceptable Documentation – Micro-Tags Submitted Without Prescription Record Hardcopy .....	11
Figure 10: Examples of Unacceptable Documentation – Patient Pickup Signature Log Accompanied by Micro-Tag .....	12
Figure 11: Example of Unacceptable Documentation – Insurance Tax Summary .....	12
Figure 12: Example of Medication Order.....	14
Figure 13: Example of Acceptable Medication Order Documentation .....	15
Figure 14: Example of Acceptable Medication Order Documentation .....	15
Figure 15: Example of Mapped Medication Order.....	16
Figure 16: Example of Micro-Tag .....	17
Figure 17: Example of Unacceptable Documentation – Refill List.....	17
Figure 18. Example of Unacceptable Documentation – MAR Form.....	18
Figure 19: Example of Unacceptable Documentation – Refill Request .....	19
Figure 20: Example of Unacceptable Documentation – Screenshot of Electronic Refills and Order Processing File .....	20
Figure 21: Example of Unacceptable Documentation – Internal Audit Report.....	20
Figure 22: Example of Unacceptable Documentation – Packing Lists .....	21
Figure 23: Example Claim Detail File .....	23
Figure 24: Tab 1, Instructions .....	24
Figure 25: Tab 2, PDE Identifying Data Elements .....	24
Figure 26: Tab 3, Data Element Reference .....	25
Figure 27: Naming Conventions for Prescription Record Hardcopies or Medication Orders .....	27
Figure 28: Example of Naming Convention and Upload Format for a Single Zip File ...	28
Figure 29: Missing Documentation Form.....	30
Figure 30: CMS Physician Attestation Form.....	32

## Introduction

The Centers for Medicare & Medicaid Services (CMS) is conducting a documentation review to validate the accuracy of calendar year (CY) 2024 Part D Prescription Drug Event (PDE) data. This analysis determines whether drugs prescribed by medical providers were received by beneficiaries and were billed appropriately to Medicare Part D contracts and, ultimately, to CMS. This process is referred to as the Medicare Part D Improper Payment Measure (IPM).

The Submission Instructions were developed to support those Part D sponsors that have had PDEs selected for the CY 2024 Part D IPM by providing an overview of the process and submission requirements. The purpose of this document is to:

- Describe applicable [records maintenance expectations and requirements](#).
- Provide a [Part D IPM overview](#) and timeline for CY 2024.
- Identify [Part D IPM supporting documentation](#) required for submission.
- Discuss how to [identify selected PDE records](#).
- Review the [submission process](#).
- Identify [best practices](#).
- Provide the best [contact information](#) should Part D sponsors have further questions.

## Records Maintenance Expectations and Requirements

Part D sponsors must maintain books, records, documents, and other evidence of accounting procedures and practices for 10 years, per 42 Code of Federal Regulations (C.F.R.) § 423.505.

The 10-year records retention regulation also applies to the Part D sponsor's first-tier downstream and related entities as per 42 C.F.R. § 423.505(i). Part D sponsors' first tier downstream and related entities must contractually agree to audits and inspections by CMS and/or its designees and must provide information as requested and maintain records for a minimum of 10 years.

If a prescription drug plan (PDP) or Medicare Advantage Prescription Drug (MAPD) plan is discontinued, merged, or acquired by another Part D sponsor, the "gaining" Part D sponsor is still required to provide access to that Part D sponsor's documents and information for a period of 10 years. All historical records for Part D sponsors that are acquired must be transferred from the old Part D sponsor to the new Part D sponsor. These regulations for PDPs and MAPD plans are found in 42 C.F.R. § 423.505(d). Gaining Part D sponsors should make every effort to acquire the required supporting documentation by contacting the appropriate records maintenance department or personnel.

Federal regulation mandates participation in the audit per 42 C.F.R § 423.505(b)(10).

Federal regulation 42 C.F.R. § 423.322(a) regarding disclosure of information states that CMS' payments to Part D sponsors are conditioned upon provision of information to CMS that is

necessary to carry out Subpart G - Payments to Part D Plan Sponsors For Qualified Prescription Drug Coverage, or as required by law. Your cooperation with this data validation activity is required. Organizations that do not comply with this requirement or that have poor performance identified through CMS oversight may be subject to remedies available under law, including enforcement actions under 42 C.F.R. Parts 423, Subparts K and O, which may include civil money penalties, enrollment sanctions, or contract terminations.

## **Part D IPM Overview**

Each year, CMS conducts a documentation review in support of the Part D IPM. This analysis determines whether drugs prescribed by medical providers were received by beneficiaries and were appropriately submitted to CMS via PDE submissions.

CMS, together with its contractor, collects and reviews documentation from Part D sponsors to substantiate a sample of PDE records selected as part of the Part D IPM. The PDE records in the sample that correspond to the Part D sponsor's contract are made available to Part D sponsors on the Health Plan Management System (HPMS) Part D IPM Module through the PDE Record Identifier spreadsheet. The HPMS Part D IPM Module also allows for sponsors' upload of Part D IPM documents and data (i.e., supporting documentation) for assigned PDE\_IDs, such as prescription record hardcopies and Claim Detail Files (CDFs).<sup>1</sup>

## **Part D Sponsor Responsibilities**

Responsibilities for Part D sponsors with PDE records selected for this review include the following tasks:

1. Review email notification from CMS that the PDE Record Identifier spreadsheet, which contains sampled PDE records' identifying data elements, is available for download.
2. Log on to the HPMS Part D IPM Module: [hpms.cms.gov](http://hpms.cms.gov).
3. Download the PDE Record Identifier spreadsheet from the HPMS Part D IPM Module.
4. Contact the appropriate pharmacy benefit managers (PBMs) and/or pharmacies to collect the supporting documentation required for each sampled PDE record.
5. Submit the supporting documentation via the HPMS Part D IPM Module.
6. Communicate with CMS and its contractor regarding submission statuses via the HPMS Part D IPM Module Discussion Board.

---

<sup>1</sup> Instructions for accessing and using the HPMS Part D IPM Module can be found in the HPMS Plan User Guide, which can be found in the HPMS Part D IPM Module under System User Guide.

## Part D IPM Timeline

Following is the timeline for the CY 2024 Part D IPM process.

Activity	Date(s)
CMS notifies selected Part D sponsors of participation in the CY 2024 Part D IPM process. Part D sponsors can download the PDE Record Identifier spreadsheet.	January 9, 2026
CMS requests Part D sponsors identify no more than five points of contact (POCs) who will work with CMS throughout the Part D IPM process. Sponsors should submit requests for new users who do <u>not</u> have an active CMS user ID and for all users who have an active CMS user ID with access to HPMS, but not the Part D IPM Module, to <a href="mailto:hpms_access@cms.hhs.gov">hpms_access@cms.hhs.gov</a> . Refer to the “Requesting Access to the HPMS Part D IPM Module” document in the Part D IPM Module Document Library for further details.	January 10–23, 2026
HPMS Part D IPM Module is open, and Part D IPM Submission Instructions are available.	January 23, 2026
Submission Window Opens: 12-week submission window begins.	January 23, 2026
Part D sponsors gather supporting documentation from pharmacies and PBMs and submit documentation to the HPMS Part D IPM Module on a rolling basis.	After the submission window begins
Early Submission Deadline: Part D sponsors that have uploaded prescription record hardcopy/medication order supporting documentation to the HPMS Part D IPM Module by this date will receive results from the element checks (see <a href="#">Verification Checks and Resubmission</a> ), as well as an Interim Findings Report (IFR) detailing preliminary results. Element checks will not be provided for supporting documents submitted after this date.	March 6, 2026
Part D sponsors that have participated in early submission and find through the elements checks and IFR that they have incomplete supporting documentation may upload additional files with complete documentation by resubmitting before the final submission deadline.	
Element check status and IFR provided to Part D sponsors that submitted prescription record hardcopy/medication order supporting documentation prior to the early submission deadline.	March 27, 2026
Final Submission Deadline: Part D sponsors complete uploading of supporting documentation to the HPMS Part D IPM Module by this date. Documentation must be received by 11:59 p.m., PT on this date to be considered for the Part D IPM validation review.	April 17, 2026
Ongoing engagement by CMS and its contractor with Part D sponsors via the HPMS Part D IPM Module Discussion Board. Part D sponsors upload additional information, if necessary.	Throughout the submission and review process
CMS notifies selected Part D sponsors of the final disposition of their selected PDEs in their Final Findings Report (FFR).	December 2, 2026

Activity	Date(s)
Selected Part D sponsors review their FFR and concur or non-concur with the findings.	Within 60 days of the FFR release

## Part D IPM Supporting Documentation

Generally, Part D sponsors must submit the following two types of supporting documentation: a CDF and a prescription record hardcopy *or* a medication order. A table with the Part D IPM Document Types is presented below.

Part D IPM Document Type	Frequency
1. CDF	One per Contract for all PDEs
2. Prescription Record Hardcopy <i>or</i> a Medication Order (for long-term care [LTC] pharmacies)  If the prescription originates from a mail or retail pharmacy, a copy of the prescription record hardcopy must be submitted for that PDE record. If the prescription originates from an LTC pharmacy, a copy of the medication order must be submitted along with any supplemental documents, if applicable, for that PDE record.	One per PDE record
3. Supplemental Documentation  For an LTC medication order that is not signed by a provider with prescriptive authority, one of the following options for supplemental documentation must be copied together with the medication order into one PDF using the current prescription record hardcopy naming convention:  I. <u>Medical Chart</u> : A physician-signed page from the medical chart referencing order in notes, a dictation note in the medical chart stating orders have been reviewed and approved by a physician, etc. The entire medical chart does NOT need to be provided, but supplemental documentation from the medical chart that supports the unsigned LTC medication order should be provided; or II. <u>Attestation</u> : A Physician/Authorized Prescriber CMS Attestation for LTC Medication Order form completed and signed by the provider; or III. <u>Chart Review Log</u> : A patient or provider chart review log signed by a provider with prescriptive authority showing review and approval of the beneficiary's medication order.	One per PDE record when an LTC medication order is not signed by a provider with prescriptive authority

Part D IPM Document Type	Frequency
<p>4. Optional Documentation</p> <p>I. <u>Medication Administration Record</u>: For LTC pharmacies, the pharmacy-generated Medication Administration Record (MAR) (if the pharmacy generates the MAR for the facility and if one is available) is not required documentation but is useful during the review process. The MAR can be either a copy of a manual MAR or a copy of an electronic MAR (eMAR). The MAR should include the drug name and strength corresponding to the drug name and strength in the PDE sample identifiers. (Note that this optional documentation does not have to be a completed MAR from the facility.)</p> <p>II. <u>Micro-Tag</u>: Submitting the computer-generated micro-tag is helpful to the review process, if it is available, for both retail/mail order prescription record hardcopies and LTC medication orders. The micro-tag is the computer-generated “sticker” that summarizes the prescription information.</p> <p>III. <u>Prior Authorization Records</u>: Submitting prior authorization records used to approve the PDE is helpful to validate a proper Part D dispensation.</p> <p>IV. <u>Post Reconciliation Adjustment Details</u>: Submitting additional information for any PDEs that have been adjusted post-reconciliation is helpful to validate any differences between the PDE and provided documentation.</p>	One per PDE record

### **Best Practices for Supporting Documentation**

All supporting documentation submitted by the final submission deadline will undergo the Part D IPM process; thus, please submit the best supporting documentation you can obtain, even if it is incomplete.

Please follow these guidelines when gathering and preparing supporting documentation for submission:

- **All supporting documentation must correspond to the PDE records in the sample.** Do not submit documents or data that correspond to dates of service other than the PDE record date or an adjusted version of the sampled PDE record made after the CMS final PDE submission deadline for Part D reconciliation of June 27, 2025. If the PDE has been adjusted prior to this date, send supporting documentation corresponding to the PDE submitted for reconciliation. See [Appendix A](#) for CMS' policy on adjusted PDE records.
- **Supporting documentation must align with the drug name and drug strength on the PDE record.** Drug name and strength will be included in the PDE identifiers provided via the HPMS Part D IPM Module.

- **Data submitted in the CDF must be in .xlsx format.** Use data from the selected PDE, queried from your data warehouse, to assemble the file. Submit data using the template provided. A data dictionary is also included in the template to provide a description of the data requested in each field.
- **Prescription record hardcopies/medication orders supporting documentation must be legible images (e.g., Adobe PDF, GIF, JPEG, BMP).** Review each document carefully for legibility before uploading and submitting via the HPMS Part D IPM Module. Prescription record hardcopies printed on tamper-proof paper with watermarks are typically used to prevent duplication and deter fraud. These watermarks of “void” or “illegal” appear on photocopies and obscure the prescription writing, making them illegible and rendering them unusable during extraction of required data elements in the review process. In this case, inclusion of a micro-tag can help inform what information is on the prescription hardcopy.

The following sections describe each supporting document, including the format of the document, what the document typically includes, and the minimum data elements that must be included in the document.

### **Prescription Record Hardcopy (Mail/Retail Pharmacies)**

The prescription record hardcopy is the original document from the prescriber (e.g., medical provider). This is the document (paper or electronic) presented to the pharmacy for dispensing. State and federal regulations require that prescription record hardcopies be retrievable by the pharmacy dispensing the prescription.

Attestations submitted by medical providers **do not** serve as valid replacements for the prescription record hardcopy in the retail/mail order setting. Physician attestations will be accepted as supplemental documentation **only** to validate a medication order (LTC pharmacy) not signed by a provider with prescriptive authority.

The prescription record hardcopy submitted for the Part D IPM process **must** include the following data elements:

- Patient name
- Drug name (active ingredient)
- Drug strength
- Dispense as Written (DAW) product selection (if applicable)
- Prescriber name
- Prescriber signature (provider with prescriptive authority)
- Prescription date
- Quantity
- Directions for use


This supporting documentation must be provided in the form depicted in Figure 1. Please note, an acceptable prescriber signature may take many different forms. Electronic signatures are acceptable for electronically transmitted documents, while a written signature will be required for written prescriptions. For telephoned prescriptions, a prescriber signature is not needed if the order is phoned directly to the pharmacist. Each signature will be reviewed on a case-by-case basis and compared with the PDE record for accuracy.

Figure 1 shows examples of retail/mail prescription record hardcopies. The front and back of the prescription record hardcopy are requested as they may contain notes that provide documentation of any changes made to the written prescription at the point of service. There is no need to submit the back of the prescription record hardcopy if it is blank.

**Figure 1: Examples of Acceptable Prescription Record Hardcopies**

<b>Richard Fast, M.D.</b> Chicago Medical Group 3000 S. Michigan Avenue Chicago, IL 60619 Phone: (312) 949-7000      Fax: (312) 949-7001 LICENSE#: IL 93824      DEAW#: RF 20398678	
<b>Name:</b> MARY PALTRW <b>Address:</b> 2645 MULBERRY LANE TOLEDO, OH 54360	<b>DOB:</b> 6/18/1951 <b>Age:</b> 58 years <b>Date:</b> 7/17/2024
<b>RX:</b> Ciloxan Eye Drops 0.3 % <b>SIG:</b> Apply 2 drop(s) in left eye every 4-6 hours for 10 days <b>QUANTITY:</b> 1 bottle(s) <b>REFILLS:</b> 3	
	
<small>THIS PRESCRIPTION WILL BE FILLED GENERICALLY UNLESS PRESCRIBER WRITES 'd a w' IN THE BOX BELOW</small>	
<input type="checkbox"/> Dispense As Written	

*Note: Fictitious beneficiary*



*Note: Fictitious Beneficiary*

#### **Optional Documentation: Micro-Tags**

The micro-tag is the computer-generated “sticker” that summarizes the prescription information. The micro-tag aids reviewers when validating the prescription record hardcopy. **It does not replace the prescription record hardcopy and will not be accepted if submitted without the original prescription record hardcopy.**

If available, a copy of the micro-tag should be submitted. **The micro-tag should be scanned together into one image with the prescription record hardcopy (preferably in PDF format).** See Figure 2 for an example of a micro-tag.

**Figure 2: Example of Micro-Tag**

Rx#:60999999	DOB: 1/1/1989	FILL DATE: 9/1/2024
Dobson, Joe		233 Elm St, Histown, FL 22222
PRAVACHOL 40 MG	QTY: 30 TAB	11111-2222-33 (Acme Drug)
Johnson, Allen	DEA: BJ1111111	RPh:XXX
Copay: \$10.00	Ins. Paid: \$45.87	Auth# 1234123456785678

*Note: Fictitious beneficiary*

The examples depicted in Figure 3 represent examples of acceptable prescription record hardcopy documentation. Figures 4 through 11 depict examples of unacceptable prescription record hardcopy documentation.

**Figure 3: Examples of Acceptable Prescription Record Hardcopy Documentation**

Name:	Jane Doe				Date: 10/25/2024
DRUG	MG/CC	SIG	QTY	REFILLS	
Amoxicillin	500	PO Q12H	28	0	
John Smith, M.D.					
Dispense as Written			Substitution Permitted		

*Note: Fictitious beneficiary*

<b>TELEPHONED PRESCRIPTION</b>				
NAME	John Doe			
ADDRESS				
PHONE#	RY	Time	DELIVER	WILL CALL
ORIGINAL Rx No.	DO NOT REFILL <input checked="" type="checkbox"/> REFILL <input checked="" type="checkbox"/> TIMES <u>12</u>			
<p><b>R</b> Lipitor 40mg 14 No Qam</p>				
LABEL	Yes <input type="checkbox"/>	No <input type="checkbox"/>	<u>John</u>	
Dispense as Written		Doctor		
Substitution Permitted	Yes	Pharmacist		
DEA No. <u>ITEM 12345</u>				

*Note: Fictitious beneficiary*

**Figure 4: Example of Unacceptable Documentation – Prescription History**

Prescription History							
<b>Doe, Jane</b>							
<b>Demographic Detail</b>							
Age	Gender	SSN	Alt SSN	Zip	11111		
41	F	XXX-XX-XXXX					
<b>Prescription Detail</b>							
Rx #	Label	Qty	Fill Date	Days Supply	Refill #	Total Refills	
1111111	Amantadine 100 mg cap	60	010124	30	0	0	
	Prescriber: Smith, J.			Pharmacy: XXX Pharmacy			
Rx #	Label	Qty	Fill Date	Days Supply	Refill #	Total Refills	
2222222	Ambien 10 mg tab	30	010124	30	0	0	
	Prescriber: Smith, J.			Pharmacy: XXX Pharmacy			
Rx #	Label	Qty	Fill Date	Days Supply	Refill #	Total Refills	
3333333	Augmentin 500-125 tab	21	010124	7	0	0	
	Prescriber: Smith, J.			Pharmacy: XXX Pharmacy			
<b>Prescriber Detail:</b>							
Address	Phone	DEA	NPI				
2 Elm St, Anywhere, State 11111	111-555-1234	AS1111111	1234567891				
<b>Pharmacy Detail:</b>							
Address	Phone	NPI	NCPDP				
10 Elm St, Anywhere, State 11111	111-555-5678	AS3333333	1234512345		1112223		
<b>Drug Detail:</b>							
Drug: AMBIEN 10 MG TABLET	Drug Code	Dosage Form	Strength	Route Description	HIC Class		
	00024542131	TABLET	10 MG	ORAL	Sedative/Hypnotic Non-Barbiturate		
<b>Disease Descriptions</b>							
Insomnia	<b>Side Effects</b>						
	Insomnia, Impaired Cognition, Nightmares, Agitation, Depression, Diplopia, Visual Changes, Hypotension, Drowsiness, Amnesia, Vertigo, Dizziness, Skin Rash, Headache, Nausea, Vomiting, Diarrhea, Falling, Allergic Reactions, Irritability						

*Note: Fictitious beneficiary*

**Figure 5: Example of Unacceptable Documentation – Pharmacy Attestation**

March 5, 2024	
In reference to prescription request for Jane Doe	
Rx: Atorvastatin 10 mg	
<p>Based on the origin code associated with this claim, this order was phoned in. Our internal label was used as a hard copy, therefore no written prescription exists.</p> <p>The undersigned certifies; (a) that the person for whom the prescription was written is eligible for benefits; (b) that they have received the prescription; (c) that they authorize the release of all information contained in this log, the prescription to which it corresponds and subsequent claims to parties concerned; (d) that they are the patient for whom this prescription is being obtained or are authorized to execute this consent on behalf of such persons; (e) that this medication is not for an on the job injury or covered by any other insurance plan and (f) that they assign payment for this transaction directly to the pharmacy shown above.</p> <p>Signature: _____</p>	

*Note: Fictitious beneficiary*

**Figure 6: Example of Unacceptable Documentation – Pharmacy Transaction File**

Rx #: 012345	Batch #: 572	Patient Facility: Evergreen
Last Fill: 03/22/2024	Qty: 30	Date: 04/20/2024
<p>Allergy: PCN            Product Ordered: Ambien 10 MG Tablet      Package Size: 100            NDC: 00024-5421-31            Product Substituted: Zolpidem 10 MG Tablet      Package Size: 100            NDC: 00054-0087-25            Directions: 1T QD.....Take one tablet by mouth daily</p>		
Qty Dispensed: 30	Quantity Remaining: 30	
# of labels: 1	PRN (Y/N)?: Y	
Expire Date: 04/20/2025	Total Fills: 2	Rx Origin: 0
Label: Zolpidem 10 MG Tablet	Substitution Ok? Y	DAW: 0
Next fill: 05/20/2024	Schedule: C-IV	
ICD9:	RPh1: ABC	

*Note: Fictitious beneficiary*

**Figure 7: Example of Unacceptable Documentation – Pharmacy Drug Utilization Review (DUR) Report**

Pharmacy DUR Report						
1/2/2024 14:26:54		Page 1				
Patient Name	Rx No.	Drug Name	Qty	DS	Fill date	Sig
Jane Doe	12345	Amlodipine 10mg	30	30	1/2/2024	One tablet by mouth daily
	12346	Atorvastatin 10mg	30	30	1/2/2024	One tablet by mouth daily
	12347	Zolpidem 10mg	30	30	1/6/2024	One tablet by mouth at bedtime
	12348	Amoxicillin 500mg	30	10	1/10/2024	One capsule by mouth 3x daily
	12349	Nexium 40mg	30	30	1/10/2024	One capsule by mouth daily
	12340	Mirtazapine 15mg	30	30	1/10/2024	One tablet by mouth daily
John Doe	12351	Aricept 10mg	30	30	1/19/2024	One tablet by mouth daily
	12352	Levothyroxine 100mcg	30	30	1/19/2024	One tablet by mouth daily
	12353	Simvastatin 40mg	30	30	1/28/2024	One tablet by mouth daily
	12354	Coreg CR 20mg	30	30	1/28/2024	One tablet by mouth daily
	12355	Tramadol 50mg	90	30	1/28/2024	One tablet by mouth 3x daily PRN

*Note: Fictitious beneficiary*

**Figure 8: Example of Unacceptable Documentation – Patient Pickup Signature Log**

Rx #	Fill Date	Pickup Date & Time	Decline Counseling	Drug Name	Quantity	Patient Paid	Total	Signature
669230	10/29/24	10/29/24 5:30pm	YES	Simvastatin 20mg	30	\$5.00	\$5.00	<i>Unacceptable Document</i>

*Note: Fictitious beneficiary*


**Figure 9: Example of Unacceptable Documentation – Micro-Tags Submitted Without Prescription Record Hardcopy**

Rx#:60999999	DOB: 1/1/1989	FILL DATE: 9/1/2024
Dobson, Joe		233 Elm St, Histown, FL 22222
PRAVACHOL 40 MG	QTY: 30 TAB	11111-2222-33 (Acme Drug)
Johnson, Allen	DEA: BJ1111111	RPh:XXX
Copay: \$10.00	Ins. Paid: \$45.87	Auth# 1234123456785678

*Note: Fictitious beneficiary*

**Figure 10: Examples of Unacceptable Documentation – Patient Pickup Signature Log Accompanied by Micro-Tag**

Rx #	Fill Date	Pickup Date & Time	Decline Counseling	Drug Name	Quantity	Patient Paid	Total	Signature
669230	10/29/24	10/29/24 5:30pm	YES	Atorvastatin 10mg	30	\$5.00	\$5.00	<i>Unacceptable Document</i>



*Note: Fictitious beneficiary*

**Figure 11: Example of Unacceptable Documentation – Insurance Tax Summary**

July 1, 2024		Tax Insurance Summary					Page 1	
NDC#	Days	Rx#	Dr. J. Smith	N/R	Date	Qty.	Amount	
Metoprolol 50mg	30				06/30/2012	30	\$0.00	
56023-0403-01								
Pantoprazole 40mg	30			N	6/30/2012	15	\$5.20	
45253-2131-12								

Pharmacist: [signature] Date: 7/01/2024

*Note: Fictitious beneficiary*

### **Medication Order (LTC Pharmacies)**

If the PDE record was processed by an LTC pharmacy, the medication order must be submitted for that PDE record. Part D sponsors should submit any supplemental or optional documentation or explanations as needed. Any supplemental or optional information must be submitted as part of the same image, meaning they should be scanned together (preferably in PDF format). Such optional information includes the MAR and/or computer-generated micro-tag, if available, for that PDE record. Do not send blank MAR template forms used by the facility or MARs containing information not aligning to the specific drug order being reviewed.

LTC pharmacies typically use a prescription record that is different from that used by retail or mail-order prescriptions. The LTC prescription record is usually a page of the patient's medical chart where the prescriber has written the medication order. This page may include other medical directives and may not be as complete or as standardized in format as the prescription record used by retail and mail-order pharmacies.

The medication order submitted for the Part D IPM process **must** include the following data elements:

- Patient name
- Drug name (active ingredient)
- Drug strength
- DAW product selection (if applicable)
- Prescriber name
- Prescriber signature (provider with prescriptive authority)
- Prescription date
- Directions

This documentation must be provided in the following form:

- Image (front and back) of the actual medication order (see Figure 12 for an example).
- If supplemental or optional documentation or explanations are needed, they should be submitted together with the medication order. An example of optional documentation is micro-tag images (see Figure 16 for an example). Make sure to circle or identify the required data elements before creating and submitting the image file. These documents should all be scanned together into one image (preferably in PDF format). Note that electronic history, transaction screenshots, MARs, and refill or packing lists from the pharmacy or LTC facility do not serve as a substitute for the medication order but may be submitted to provide additional information about the medication order.

Figures 12 through 14 are examples of acceptable medication orders. Figure 15 depicts an example of a mapped medication order. Figure 16 depicts an example of a micro-tag. Figures 17 through 22 show examples of unacceptable medication order supporting documents.

Figure 12: Example of Medication Order

<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">S or U (scheduled or unscheduled visit) or T<sub>FU</sub> (telephone follow-up) or T<sub>U</sub> (telephone urgent) or E<sub>FU</sub> (email follow-up)</td> <td>Date: _____ S.U.T<sub>FU</sub> T<sub>U</sub> or E<sub>FU</sub>: _____ HCP ID#: _____</td> </tr> <tr> <td colspan="3"> <b>Physical Assessment</b>            Temperature p/m            Pulse p/m            Respiration p/m            Blood Pressure p/m            Height p/m            Weight p/m            Chest sounds q visit            02 Sat (if available)         </td> </tr> <tr> <td style="text-align: center;">*D</td> <td style="text-align: center;">*ND</td> <td></td> </tr> <tr> <td colspan="3"> <b>Asthma Control:</b>            Cough, wheeze or chest tightness (&lt;4/ds/wk)         </td> </tr> <tr> <td colspan="3">           Wake at night (&lt;1/wk)            Physical activity limited due to asthma            Needs Reliever with exercise            Needs Reliever (&lt;4/wk)            Exacerbations (hospital admit, ER visit, Walk-in Clinic) since last visit            School/work absence since last visit         </td> </tr> <tr> <td colspan="3"> <b>Spirometry</b>            FEV<sub>1</sub> pre            FEV<sub>1</sub> post            FEV<sub>1</sub> % change            PEF pre            PEF post            PEF % change         </td> </tr> <tr> <td style="text-align: center;">D</td> <td style="text-align: center;">ND</td> <td></td> </tr> <tr> <td colspan="3"> <b>Review</b>            Definition of Asthma            Action Plan - (ACP)            Action Plan - (verbal)            Med. Admin. Technique            Warning signs            Trigger factors            Environmental control            Coping strategies         </td> </tr> <tr> <td colspan="3"> <b>Medications</b>  <b>Current</b>    <b>Prescribed</b> </td> </tr> <tr> <td colspan="3">           Monitor potential side effects            Height/osteoporosis, etc.         </td> </tr> <tr> <td style="text-align: center;">D</td> <td style="text-align: center;">ND</td> <td></td> </tr> <tr> <td colspan="3"> <b>Referrals</b>            Asthma Education Program            Asthma Support Group            Specialist         </td> </tr> <tr> <td style="text-align: center;">D</td> <td style="text-align: center;">ND</td> <td></td> </tr> </table>	S or U (scheduled or unscheduled visit) or T <sub>FU</sub> (telephone follow-up) or T <sub>U</sub> (telephone urgent) or E <sub>FU</sub> (email follow-up)		Date: _____ S.U.T <sub>FU</sub> T <sub>U</sub> or E <sub>FU</sub> : _____ HCP ID#: _____	<b>Physical Assessment</b> Temperature p/m Pulse p/m Respiration p/m Blood Pressure p/m Height p/m Weight p/m Chest sounds q visit 02 Sat (if available)			*D	*ND		<b>Asthma Control:</b> Cough, wheeze or chest tightness (<4/ds/wk)			Wake at night (<1/wk) Physical activity limited due to asthma Needs Reliever with exercise Needs Reliever (<4/wk) Exacerbations (hospital admit, ER visit, Walk-in Clinic) since last visit School/work absence since last visit			<b>Spirometry</b> FEV <sub>1</sub> pre FEV <sub>1</sub> post FEV <sub>1</sub> % change PEF pre PEF post PEF % change			D	ND		<b>Review</b> Definition of Asthma Action Plan - (ACP) Action Plan - (verbal) Med. Admin. Technique Warning signs Trigger factors Environmental control Coping strategies			<b>Medications</b> <b>Current</b>  <b>Prescribed</b>			Monitor potential side effects Height/osteoporosis, etc.			D	ND		<b>Referrals</b> Asthma Education Program Asthma Support Group Specialist			D	ND		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">1</td> <td style="width: 80%; text-align: center;">John Doe</td> <td style="width: 10%;">6</td> </tr> <tr> <td colspan="3"> <b>OFFICE VISITS</b>            ADDRESS: _____            OCCUPATION: _____            EMPLOYER: ESL Student            DATE / VITAL SIGNS: BP: 130/85, HR: 80, WT: 65 kg, T: 98.6°F, P: 78         </td> </tr> <tr> <td colspan="3">           INSURANCE NO. _____            PHONE (Home): _____ (Work): _____            DOB: 1967-05-05 AGE: 57         </td> </tr> <tr> <td colspan="3">           SUBJECTIVE: _____            OBJECTIVE: _____            ASSESSMENT: _____            PLANS: _____         </td> </tr> <tr> <td colspan="3" style="text-align: right;">May - 2 - 2024</td> </tr> <tr> <td colspan="3">           HPI: on &amp; off Hx of cough, wheeze &amp; chest tightness x 1 year. The symptom started gradually and now is constant. 2 month ago was ER admission for asthma exacerbation. Night cough especially disturbing for the pt. She is an Salbutamol one mcg H/ day is helpful but not totally. She has asthma from dust &amp; fogweed. Smoking also aggravate her symptoms by husband smoke but outside the house. She immigrated from Somalia 3-5 years ago and can't recall such symptoms in the past. C fever, night sweat, wt loss of fatigue, there is very scanty ptalm. With cough there is also some sub w chest r/r to 120-130. 2 mo ago had sputum &amp; the result was equivocal. PPD skin test was also less than 5 mm. CBC &amp; RMI: WNL.         </td> </tr> <tr> <td colspan="3">           PMH: w dx w T&amp;D the age of 17 and was dx TB neck for 1 year. Since the dx he been no sign of TB relaps. P: Rheumatic fever at her teens on as a result of chronic valvular dysfunction. Oby. Gym. Hx: has 4 children, her first pregnancy was also complicated with pregnancy induced HTN. She had a miscarriage 5 years ago. FMH: Father died at 65 y/o because of gun shot wound. Grandmother died DM. Hx of Smoking, O/T/OH, lives w her children and in a supportive living facility/UKO         </td> </tr> <tr> <td colspan="3" style="text-align: right;">↓</td> </tr> <tr> <td colspan="3"> <b>Medication Order</b>            Add: Salbutamol 800 mcg H/ day            Fluvent 100            &gt; OCP         </td> </tr> <tr> <td colspan="3" style="text-align: right;">5</td> </tr> </table>	1	John Doe	6	<b>OFFICE VISITS</b> ADDRESS: _____ OCCUPATION: _____ EMPLOYER: ESL Student DATE / VITAL SIGNS: BP: 130/85, HR: 80, WT: 65 kg, T: 98.6°F, P: 78			INSURANCE NO. _____ PHONE (Home): _____ (Work): _____ DOB: 1967-05-05 AGE: 57			SUBJECTIVE: _____ OBJECTIVE: _____ ASSESSMENT: _____ PLANS: _____			May - 2 - 2024			HPI: on & off Hx of cough, wheeze & chest tightness x 1 year. The symptom started gradually and now is constant. 2 month ago was ER admission for asthma exacerbation. Night cough especially disturbing for the pt. She is an Salbutamol one mcg H/ day is helpful but not totally. She has asthma from dust & fogweed. Smoking also aggravate her symptoms by husband smoke but outside the house. She immigrated from Somalia 3-5 years ago and can't recall such symptoms in the past. C fever, night sweat, wt loss of fatigue, there is very scanty ptalm. With cough there is also some sub w chest r/r to 120-130. 2 mo ago had sputum & the result was equivocal. PPD skin test was also less than 5 mm. CBC & RMI: WNL.			PMH: w dx w T&D the age of 17 and was dx TB neck for 1 year. Since the dx he been no sign of TB relaps. P: Rheumatic fever at her teens on as a result of chronic valvular dysfunction. Oby. Gym. Hx: has 4 children, her first pregnancy was also complicated with pregnancy induced HTN. She had a miscarriage 5 years ago. FMH: Father died at 65 y/o because of gun shot wound. Grandmother died DM. Hx of Smoking, O/T/OH, lives w her children and in a supportive living facility/UKO			↓			<b>Medication Order</b> Add: Salbutamol 800 mcg H/ day Fluvent 100 > OCP			5		
S or U (scheduled or unscheduled visit) or T <sub>FU</sub> (telephone follow-up) or T <sub>U</sub> (telephone urgent) or E <sub>FU</sub> (email follow-up)		Date: _____ S.U.T <sub>FU</sub> T <sub>U</sub> or E <sub>FU</sub> : _____ HCP ID#: _____																																																																				
<b>Physical Assessment</b> Temperature p/m Pulse p/m Respiration p/m Blood Pressure p/m Height p/m Weight p/m Chest sounds q visit 02 Sat (if available)																																																																						
*D	*ND																																																																					
<b>Asthma Control:</b> Cough, wheeze or chest tightness (<4/ds/wk)																																																																						
Wake at night (<1/wk) Physical activity limited due to asthma Needs Reliever with exercise Needs Reliever (<4/wk) Exacerbations (hospital admit, ER visit, Walk-in Clinic) since last visit School/work absence since last visit																																																																						
<b>Spirometry</b> FEV <sub>1</sub> pre FEV <sub>1</sub> post FEV <sub>1</sub> % change PEF pre PEF post PEF % change																																																																						
D	ND																																																																					
<b>Review</b> Definition of Asthma Action Plan - (ACP) Action Plan - (verbal) Med. Admin. Technique Warning signs Trigger factors Environmental control Coping strategies																																																																						
<b>Medications</b> <b>Current</b>  <b>Prescribed</b>																																																																						
Monitor potential side effects Height/osteoporosis, etc.																																																																						
D	ND																																																																					
<b>Referrals</b> Asthma Education Program Asthma Support Group Specialist																																																																						
D	ND																																																																					
1	John Doe	6																																																																				
<b>OFFICE VISITS</b> ADDRESS: _____ OCCUPATION: _____ EMPLOYER: ESL Student DATE / VITAL SIGNS: BP: 130/85, HR: 80, WT: 65 kg, T: 98.6°F, P: 78																																																																						
INSURANCE NO. _____ PHONE (Home): _____ (Work): _____ DOB: 1967-05-05 AGE: 57																																																																						
SUBJECTIVE: _____ OBJECTIVE: _____ ASSESSMENT: _____ PLANS: _____																																																																						
May - 2 - 2024																																																																						
HPI: on & off Hx of cough, wheeze & chest tightness x 1 year. The symptom started gradually and now is constant. 2 month ago was ER admission for asthma exacerbation. Night cough especially disturbing for the pt. She is an Salbutamol one mcg H/ day is helpful but not totally. She has asthma from dust & fogweed. Smoking also aggravate her symptoms by husband smoke but outside the house. She immigrated from Somalia 3-5 years ago and can't recall such symptoms in the past. C fever, night sweat, wt loss of fatigue, there is very scanty ptalm. With cough there is also some sub w chest r/r to 120-130. 2 mo ago had sputum & the result was equivocal. PPD skin test was also less than 5 mm. CBC & RMI: WNL.																																																																						
PMH: w dx w T&D the age of 17 and was dx TB neck for 1 year. Since the dx he been no sign of TB relaps. P: Rheumatic fever at her teens on as a result of chronic valvular dysfunction. Oby. Gym. Hx: has 4 children, her first pregnancy was also complicated with pregnancy induced HTN. She had a miscarriage 5 years ago. FMH: Father died at 65 y/o because of gun shot wound. Grandmother died DM. Hx of Smoking, O/T/OH, lives w her children and in a supportive living facility/UKO																																																																						
↓																																																																						
<b>Medication Order</b> Add: Salbutamol 800 mcg H/ day Fluvent 100 > OCP																																																																						
5																																																																						

Note: Fictitious beneficiary

**Figure 13: Example of Acceptable Medication Order Documentation**

<b>PHYSICIAN ORDERS</b>	
<b>Medications</b>	<b>Orders</b>
05/04/2024 Amoxicillin 500mg Oral TID Ramipril 5mg Oral QD 06/06/2011 Lexapro 5mg Oral QD	05/04/2024 Lifestyle Activities: exercise as tolerated
<b>Physician Signature:</b> <i>John Smith</i>	<b>Date:</b> 06/06/2024
<b>Allergies:</b> NKDA	<b>Diagnosis:</b> 123.4 561.5 181.2
<b>Resident Name:</b> <i>Jane Doe</i>	<b>DOB:</b> xx/xx/yyyy

*Note: Fictitious beneficiary*

**Figure 14: Example of Acceptable Medication Order Documentation**

<b>Name:</b> Jane Doe	<b>Date:</b> 10/25/2024																				
<table border="1"> <thead> <tr> <th>DRUG</th> <th>MG/CC</th> <th>SIG</th> <th>QTY</th> <th>REFILLS</th> </tr> </thead> <tbody> <tr> <td>Amoxicillin</td> <td>500</td> <td>PO Q12H</td> <td>28</td> <td>0</td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> </tbody> </table>		DRUG	MG/CC	SIG	QTY	REFILLS	Amoxicillin	500	PO Q12H	28	0										
DRUG	MG/CC	SIG	QTY	REFILLS																	
Amoxicillin	500	PO Q12H	28	0																	
<i>John Smith, M.D.</i>																					
Dispense as Written      Substitution Permitted																					

*Note: Fictitious beneficiary*

Figure 15: Example of Mapped Medication Order

OFFICE VISITS		INSURANCE NO.	PAGE #	CHART #
ADDRESS		PHONE (Home)	(Work)	
OCCUPATION EMPLOYER	ESL Student	DOB 1967-05-05	AGE 57	
SUBJECTIVE		OBJECTIVE	ASSESSMENT	
DATE / VITAL SIGNS			PLANS	
BP 130/85 HT 70 WT 65 BMI 22 P 78 T 39		37 y/o F	May - 2 - 2024	
<p>PE: scattered wheezes throughout breaths - Heart: S1 &amp; S2 available however there are murmurs Q waves &amp; ST</p> <p>BP: 130/85 HT: 70 WT: 65 BMI: 22 P: 78 T: 39</p> <p>Test: PPD skin test Chest X-ray CBC, ESR, Echocardiography ECG Spirometry</p> <p>Med: Salbutamol BID</p> <p>Fluvent TID</p> <p>OCP</p> <p>CC: Cough &amp; tightness in the chest</p> <p>HPI: on &amp; off for 6 months of cough, wheezes &amp; chest tightness x 1 year. The symptom started gradually and now is constant. 2 months ago was ER admission for asthma exacerbation. Night cough especially disturbing for the patient. She is on Salbutamol 4 mcg H/Day ID is helpful but not totally. She has allergy to dust &amp; pollen, smoking also aggravate her symptoms. Her husband smokes but outside the house. She immigrated from Somalia 3.5 years ago and can't recall such symptoms in the past.</p> <p>① Fever, night sweat, but loss of fatigue, there is very scanty sputum with cough - there is also some subacute chest tightness. 2 weeks ago had sputum test &amp; the result was equivocal.</p> <p>PPD skin test was also less than 5 mm</p> <p>CBC &amp; RMP: WNL.</p> <p>PMH: W/ dx of TB at the age of 17 and was on TB meds for 1 year. Since then there has been no sign of TB relapse.</p> <p>② Rheumatology: Fever &amp; hot teens on as a result of adjuvant medication dysfunction.</p> <p>Oby. Gyn. Hx: Has 4 children, her past pregnancy was also complicated with pregnancy induced DM. She had a cesarean 5 years ago.</p> <p>FHx: Father died at 65 y/o because of gun shot wound.</p> <p>Social Hx: G smoking, G TOH, lives w/ her children &amp; husband in a supportive household. Drug allergy: UNK.</p> <p>Lauren Berkshire, MD</p>				

1. Patient Name	5. Provider with Prescriptive Authority
2. Drug Name (Active Ingredient)	6. Prescription Date
3. Drug Strength	7. Directions
4. Dispense As Written (DAW) product selection if applicable	

Note: Fictitious beneficiary

\*\*\* Please note that in this example, #3 is not applicable as the drug is available in only one strength and #4 is not applicable as this is a single source drug.

**Figure 16: Example of Micro-Tag**

Rx#:60999999	DOB: 1/1/1989	FILL DATE: 9/1/2024
Dobson, Joe	233 Elm St, Histown, FL 22222	
PRAVACHOL 40 MG	QTY: 30 TAB	11111-2222-33 (Acme Drug)
Johnson, Allen	DEA: BJ1111111	RPh:XXX
Copay: \$10.00 Ins. Paid: \$45.87 Auth# 1234123456785678		

*Note: Fictitious beneficiary*

**Figure 17: Example of Unacceptable Documentation – Refill List**

REFILL ORDERS		Check ONE box only <input checked="" type="checkbox"/> Send today _ Weekly	
<div style="border: 1px solid black; padding: 10px;"> <p>Facility: XXXXX</p> <p>Today's Date: 5/26/24</p> <p>Ordering Staff: Joan</p> <p>Pages: 1 of 3</p> </div>			
<b>Nurse Rec'd</b>	<b>Date</b>	<b>Nurse Rec'd</b>	<b>Date</b>
Amlodipine10mg	5/20/24	Amlodipine10mg	5/26/24
<b>Nurse Rec'd</b>	<b>Date</b>	<b>Nurse Rec'd</b>	<b>Date</b>
Amlodipine10mg	5/21/24		
<b>Nurse Rec'd</b>	<b>Date</b>	<b>Nurse Rec'd</b>	<b>Date</b>
Amlodipine10mg	5/22/24		
<b>Nurse Rec'd</b>	<b>Date</b>	<b>Nurse Rec'd</b>	<b>Date</b>
Amlodipine10mg	5/23/24		
<b>Nurse Rec'd</b>	<b>Date</b>	<b>Nurse Rec'd</b>	<b>Date</b>
Amlodipine10mg	5/24/24		
<b>Nurse Rec'd</b>	<b>Date</b>	<b>Nurse Rec'd</b>	<b>Date</b>
Amlodipine10mg	5/25/24		

Unacceptable Document












## Calendar Year 2024 Part D Improper Payment Measure

**Figure 18. Example of Unacceptable Documentation – MAR Form**

*Note: Fictitious beneficiary*

**Figure 19: Example of Unacceptable Documentation – Refill Request**

Pharmacy Suite M		PLEASE USE NEW SHEET EACH FAX	
Unacceptable Document			
		Facility & Station:	
		Date:	5-12-24
		Ordered By:	
is on 704A	 <b>COSEAK 50MG</b> <b>TITIOP</b> RX 704A-0952-54 04/12/2024 30 60 120 1000 04/12/2024	 <b>PAROXETINE 20MG</b> <b>TITIOP</b> RX 704A-0728-70 04/12/2024 60 120 1000 04/12/2024	
on 6002B Blue 2agp	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024	 <b>SIMVASTATIN</b> <b>TITIOP</b> RX 6002B-0480-01 04/12/2024 30 60 120 1000 04/12/2024	 <b>ACETYL CHOL</b> <b>TITIOP</b> RX 6002B-0484-4 04/12/2024 60 120 1000 04/12/2024
		Refill Request	
	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024	 <b>ACETYL CHOL</b> <b>TITIOP</b> RX 6002B-0484-4 04/12/2024 60 120 1000 04/12/2024	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024
	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024
	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024	 <b>AMITRIPTYLINE CAPSULE</b> <b>TITIOP</b> RX 6002B-0476-4 04/12/2024 30 60 120 1000 04/12/2024

**Figure 20: Example of Unacceptable Documentation – Screenshot of Electronic Refills and Order Processing File**

Start Dt/Tme 8/16/24 2:35pm	Exp Dt 8/16/25 D/S 30 Disp 30									
Stop Dt/Tme 8/17/24 1:34pm	Lst Fl 8/15/24 Ref 11 Rem Quan 30									
Notes: Auth By Auth #										
<i>Unacceptable Document</i>										
Opt	Rx Number	Drug Name	Qty	Org Dt	Lst Dt	Sig Code	Doctor	Price	PC	Rc
F5		ATENOLOL 50MG	30	081611 081711		QD		10.00		
F6		AMOXICILLIN 500MG	28	070211 000000		TID		7.00		
F7		PHENYTOIN 100MG	180	060511 060511		2T TID		10.00		
F8										
F9										

*Note: Fictitious beneficiary*

**Figure 21: Example of Unacceptable Documentation – Internal Audit Report**

12:34	04/10/2024
<i>Unacceptable Document</i>	
Patient:	
Physician:	
Facility	
Rx Date: 02 / 03 / 2024	Prep Date: 02 / 05 / 2024
Expire Date: 05 / 03 / 2024	Start Date: 02 / 05 / 2024
Discard Date:	Rx#:
	Log# 123446
	Claim ID:
Total Volume per Dose:	1 ML Days Supply: 30
Total Metric Quantity:	30 Gross Amt Due: \$20.00
Rx Description:	OMEPPRAZOLE/SODIUM BICARBONATE 20MG
Frequency:	QD
Sig:	
Allergies:	None
Dispense:	

**Figure 22: Example of Unacceptable Documentation – Packing Lists**

<u>Packing Slip</u>																				
<p>Delivery Route:</p> <p>Shipping Tote:</p> <p>Date: 05/06/2024</p> <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 10%;">Rx#</th> <th style="width: 10%;">Qty</th> <th style="width: 40%;">Medication Label Name</th> <th style="width: 10%;">Prescriber</th> </tr> </thead> <tbody> <tr> <td>123456</td> <td>BOX</td> <td>ALBUTEROL INHALER</td> <td>MPD</td> </tr> <tr> <td>221144</td> <td>BOX</td> <td>CYCLOBENZAPRINE</td> <td>LN</td> </tr> <tr> <td>528900</td> <td>BOX</td> <td>RAMIPRIL</td> <td>MPD</td> </tr> </tbody> </table> <p>By signing below you acknowledge that the items above have been received.</p> <p><u>L. Johnson</u></p>					Rx#	Qty	Medication Label Name	Prescriber	123456	BOX	ALBUTEROL INHALER	MPD	221144	BOX	CYCLOBENZAPRINE	LN	528900	BOX	RAMIPRIL	MPD
Rx#	Qty	Medication Label Name	Prescriber																	
123456	BOX	ALBUTEROL INHALER	MPD																	
221144	BOX	CYCLOBENZAPRINE	LN																	
528900	BOX	RAMIPRIL	MPD																	

*Note: Fictitious beneficiary*

### **LTC Medication Orders – Supplemental Documentation Process**

A medication order that is signed by a provider with prescriptive authority is the preferred supporting document for LTC claims for this Part D IPM process. In certain circumstances, supplemental documentation can serve as a substitute for a medication order or to cure a deficient medication order. Supplemental documentation must be copied together with the medication order into one PDF using the appropriate naming convention for the file.

Examples of supplemental documentation include:

- A completed Physician Attestation form together with a medication order that is not signed by a provider with prescriptive authority. (Only the official Physician Attestation forms as provided by CMS to Part D sponsors are acceptable.)
- An unsigned medication order accompanied with supplemental information, such as a physician-signed page from the medical chart referencing review of the order in the progress notes; a dictation note in a medical chart stating orders have been reviewed and approved by a physician; or a patient or provider chart review log signed by a provider with prescriptive authority showing review and approval of a beneficiary's medication order.

### **Claim Detail File**

For every pharmacy claim processed by a PBM, data from the processing/adjudication results are created and stored. These results contain claims adjudication details available for the PBM to review. These data are typically stored in the PBM's computer system.

The CDF submitted for the Part D IPM process must include the following data elements:

- Group ID (pre-populated)
- PDE\_ID (pre-populated)
- Medicare Beneficiary Identifier (MBI)
- Pharmacy National Provider Identifier (NPI)
- Beneficiary First Name
- Beneficiary Last Name
- Prescription service reference number (Rx Number)
- Product service ID (National Drug Code [NDC] number)
- Date of Service
- Quantity
- Days' Supply
- Ingredient Cost Paid
- Dispensing Fee Paid
- Sales Tax
- Vaccine Administration Fee
- Gross Drug Cost Below Out-of-Pocket Threshold
- Gross Drug Cost Above Out-of-Pocket Threshold
- Patient Pay Amount
- Other True Out-of-Pocket (TrOOP) Amount
- Low-Income Cost Sharing Subsidy Amount
- Patient Liability Reduction due to other payer amount
- Covered D Plan Paid Amount
- Non-Covered Plan Paid Amount
- Estimated Rebate at Point of Service (POS)
- Total Gross Covered Drug Cost Accumulator
- TrOOP Accumulator
- Reported Gap Discount
- Other TrOOP Amount Indicator
- Part D Model Indicator
- National Council for Drug Programs Pharmacy Database (NCPDP) Field D-0
- NCPDP Field 415-DF
- NCPDP Field 414-DE

This supporting documentation must be provided in the following form:

- The CDF must be submitted, unaltered, using the Microsoft Excel® template provided to each Part D sponsor via the HPMS Part D IPM Module, as shown in Figure 23. There is one Excel template for each contract. The HPMS Part D IPM Module will not accept CDFs that have had their format altered in any way.
- All data elements requested for a particular PDE\_ID must be present on the CDF (i.e., each row must be completed). The HPMS Part D IPM Module will not accept CDFs with partial information for a specific PDE\_ID.
- The quantity data element can include no more than two decimals.

- The CDF is not required to include information for all PDE\_IDs in a single CDF (that is, you may upload CDFs one PDE\_ID at a time).

**Figure 23: Example Claim Detail File<sup>2</sup>**

Group_ID	PDE_ID	MBI	Beneficiary First Name	Beneficiary Last Name	Rx Number	NDC	Pharmacy NPI	Date of Service	Quantity	Days Supply	Ingredient Cost Paid	Dispensing Fee Paid	Sales Tax	Vaccine Administration Fee	Gross Drug Cost Below Out-of-Pocket Threshold
100	H0001_2024_0001														
101	H0001_2024_0002														
102	H0001_2024_0003														
103	H0001_2024_0004														
104	H0001_2024_0005														
105	H0001_2024_0006														

Gross Drug Cost Above Out-of-Pocket Threshold	Patient Pay Amount	Other TrOOP Amount	Low Income Cost Sharing Subsidy Amount	Patient Liability Reduction Due to Other Payer Amount	Covered D Plan Paid Amount	Non Covered Plan Paid Amount	Estimated Rebate at POS	Total Gross Covered Drug Cost Accumulator	True Out-of-Pocket Accumulator	Reported Gap Discount	Other TrOOP Amount Indicator	Part D Model Indicator	NCPDP Field-DO	NCPDP Field 415-DF	NCPDP Field 414-DE	PDE ID Status
																No Response
																No Response
																No Response
																No Response
																No Response
																No Response
																No Response
																No Response
																No Response

*Note: Fictitious Beneficiaries*

### **Claim Detail Financial Fields**

Beginning in 2010, legislative changes to the definition of “negotiated price” affected the required pricing data elements. Federal Regulation 42 C.F.R. § 423.100 amends the definition of “negotiated prices” (effective for the Part D IPM CY 2010 and forward) to require that Part D sponsors base beneficiary cost-sharing and price reporting to CMS on the price ultimately received by the pharmacy or other dispensing provider, also known as the pass-through price.

The changes to the C.F.R. require that all beneficiary cost shares and accumulators on the PDE be based on the actual drug prices paid to the pharmacy provider. This Part D IPM process identifies discrepancies between the prescription record hardcopy, the CDF, and the PDE record.

### **Identifying Selected PDE Records**

The CY 2024 Part D IPM sample includes PDE records that correspond to the Part D sponsor’s contract. The PDE Record Identifier spreadsheet from the HPMS Part D IPM Module identifies which PDE records are in the review sample. An HPMS Part D IPM Module email notification is sent to the Part D sponsor noting that this spreadsheet is ready for download. After identifying the PDE records in the sample, the Part D sponsor gathers the required supporting documentation for these PDE records.

The following discussion describes the content of the PDE Record Identifier spreadsheet.

**Tab 1, Instructions:** The first tab contains instructions for identifying the PDE records that must be validated and for submission of the corresponding supporting documentation, including the

<sup>2</sup> The example here has been split for visual purposes, with each row corresponding to a unique PDE, which will be assigned a unique PDE\_ID and Group ID, and includes all data fields.



## Calendar Year 2024

### Part D Improper Payment Measure

document naming conventions. See Figure 24 for an example of Tab 1 from the PDE Record Identifier spreadsheet.

**Figure 24: Tab 1, Instructions**

**Instructions for Identifying and Validating PDE Records**

The purpose of this spreadsheet is to allow you to identify the PDE records selected for your contract. The PDE Identifying Data Elements tab presents the data elements that uniquely identify the PDE record. Each PDE record is assigned a PDE\_ID. The Data Element Reference tab includes details on each PDE identifying data element.

Once you have identified the PDE records, please complete the following steps:

1. Locate and collect PDE Validation Documents required for each PDE record.
2. Create an electronic copy of requested documentation using the following naming conventions:

PDE Validation Document	Naming Convention	Example
Retail/Mail Pharmacy	LTC Pharmacy	
Prescription Record Hard Copy	Medication Order*	PDE_ID_RxRec
PBM Claim Detail File		T0001_2024_0001_RxRec
		ContractNumber_Year_CDF
		T0001_2024_CDF

3. Log onto the website: [HPMS Part D IPM](#)  
 4. Navigate to the Part D IPM Module  
 5. Submit requested documentation via the Submission page.

For more information on data submission, refer to the Submission Guide available on the HPMS PDE Validation Module.

\* Please ensure that the required data elements in the Medication Order are properly identified. See the Submission Guide for details.

**Tab 2, PDE Identifying Data Elements:** The second tab of the spreadsheet contains the PDE ID and a set of 10 PDE data elements that uniquely identify the PDE record that must be validated. See Figure 25 for an example of Tab 2 of the spreadsheet.

Each PDE record is given a **PDE ID**. This number is assigned by CMS. It consists of the Part D sponsor Contract ID, the year of the PDE record's date of service, and a final number assigned in sequential order.

This PDE ID is used to name the Part D sponsor's supporting documentation and to communicate about PDE records with CMS and/or its contractor. **Do not use Protected Health Information (PHI) or Personally Identifiable Information (PII) when communicating about a PDE record via email or the HPMS Part D IPM Module Discussion Board. Please use the PDE ID when communicating with CMS regarding this project.**

**Figure 25: Tab 2, PDE Identifying Data Elements**

**PDE Identifying Data Elements**

Contract	H0002
Year of Service of PDEs	2024
Report Date	12/18/2024
<b>Click to view:</b>	
<a href="#">Instructions</a>	
<a href="#">Data Element Reference</a>	

**The following PDE records require validation:**

PDE_ID	Claim Control Number	PBP	Prescription Service Ref. Number	DOS	Fill Number	Service Provider ID	Service Provider ID Qualifier	Drug Name, Strength & Dosage Form	MBI	Process Date
H0002_2024_0001	74632007411 000051285104	1	1234567891	02/10/24	0	1861591166	1	FLUOXETINE HCL 40 MG CAPS	A1B4D47881C	02/10/2024
H0002_2024_0002	74632007411 000051285104	1	1234567891	03/13/24	1	1861591166	1	FLUOXETINE HCL 40 MG CAPS	A1B4D47881C	03/13/2024
H0002_2024_0003	74632007411 000051285104	1	1234567891	08/11/24	2	1861591166	1	FLUOXETINE HCL 40 MG CAPS	A1B4D47881C	08/11/2024
H0002_2024_0004	74632007411 000051285104	1	1234567891	09/14/24	1	1518135375	1	OXYBUTYNIN CL ER 10 MG TAB	A1B4D47881C	09/04/2024
H0002_2024_0005	74632007411 000051285104	1	1234567891	10/24/24	2	1518135375	1	OXYBUTYNIN CL ER 10 MG TAB	A1B4D47881C	10/24/2024
H0002_2024_0006	74632007411 000051285104	1	1234567891	11/19/24	3	1518135375	1	OXYBUTYNIN CL ER 10 MG TAB	A1B4D47881C	11/19/2024
H0002_2024_0007	74632007411 000051285104	1	1234567891	03/05/24	1	1356445324	1	AMOX-CLAV 875-125 MG TAB	A1B4D47881C	03/05/2024
H0002_2024_0008	74632007411 000051285104	1	1234567891	04/27/24	2	1356445324	1	AMOX-CLAV 875-125 MG TAB	A1B4D47881C	04/27/2024
H0002_2024_0009	74632007411 000051285104	1	1234567891	03/05/24	0	1356445324	1	AMOX-CLAV 875-125 MG TAB	A1B4D47881C	03/05/2024
H0002_2024_0010	74632007411 000051285104	1	1234567891	04/27/24	1	1265447387	1	DILTIAZEM 24HR ER 240 MG CA	A1B4D47881C	04/27/2024
H0002_2024_0011	74632007411 000051285104	1	1234567891	05/13/24	2	1265447387	1	DILTIAZEM 24HR ER 240 MG CA	A1B4D47881C	05/13/2024
H0002_2024_0012	74632007411 000051285104	1	1234567891	05/24/24	3	1265447387	1	DILTIAZEM 24HR ER 240 MG CA	A1B4D47881C	05/24/2024

The following identifiers are provided on Tab 2:

- Claim Control Number
- Plan Benefit Package (PBP) Number
- Prescription Service Reference Number
- Date of Service
- Fill Number
- Service Provider ID
- Service Provider ID Qualifier
- Drug Name, Strength & Dosage Form
- MBI
- Process Date

**Tab 3, Data Element Reference:** This tab provides further details concerning the identifying data elements in the PDE record. See Figure 26 for an example of Tab 3 of the spreadsheet. Column 1, Data Elements, offers a list of data element fields; Columns 2 and 3 provide definitions of the types of values normally found in the fields. See [Appendix B](#) for the entire list of 2024 PDE data elements.

**Figure 26: Tab 3, Data Element Reference**

<i>Data Elements</i>	<i>PDE Field Name</i>	<i>Definitions/Values</i>
PDE_ID	N/A	Field assigned by CMS to identify each unique PDE record. Consists of <i>Contract ID_Analysis Year_Sequential Number</i>
Claim Control Number	CLAIM CONTROL NUMBER	Optional Field *
PBP	N/A	Plan Benefit Package Identification Number
Prescription Service Ref Number	PRESCRIPTION SERVICE REFERENCE NO	The field length of 12 will be implemented in the Drug Data Processing System (DDPS) on January 1, 2011, in anticipation of the implementation of the NCPDP D.0 standard in 2012. Field will be right justified and filled with 5 leading zeroes. Applies to all PDEs submitted January 1, 2011, and after.
DOS	DATE OF SERVICE (DOS)	MM/DD/YYYY
Fill Number	FILL NUMBER	Values = 0–99.

Data Elements	PDE Field Name	Definitions/Values
Service Provider ID	SERVICE PROVIDER ID	When Plans report Service Provider ID Qualifier = '99' - Other, populate Service Provider ID with the default value "PAPERCLAIM" defined for TrOOP Facilitation Contract.
Service Provider ID Qualifier	SERVICE PROVIDER ID QUALIFIER	The type of pharmacy provider identifier used in field 14. 01 = National Provider Identifier (NPI); 06 = UPIN; 07 = NCPDP Provider ID; 08 = State License; 11 = Federal Tax Number; 99 = Other (Reported Gap Discount must = 0). Mandatory for standard format. For standard format, valid values are 01 - NPI or 07 - NCPDP Provider ID. For non-standard format, any of the above values are acceptable.
Drug Name, Strength, & Dosage Form	PRODUCT SERVICE ID	Root drug name, strength, and dosage form referenced from NDC number found in the product service ID PDE field.
MBI	MEDICARE BENEFICIARY IDENTIFIER	Replacement for the Social Security Number-based Health Insurance Claim Number (HICN).
Process Date	N/A	Data Process Date, MM/DD/YYYY

\* Please note, the Claim Control Number for records obtained through consolidation of a plan or plan sponsor may not match the format of your current claims system.

## Submission Process

After downloading the PDE Record Identifier spreadsheet to identify sampled PDE records, requests for supporting documentation must be made for those PDE records from pharmacies and PBMs. As a reminder, all supporting documentation submitted by the final submission deadline will undergo the Part D IPM process. Part D sponsors, CMS, and its contractor communicate via the Discussion Board feature on the HPMS Part D IPM Module if any questions or problems arise regarding the submission process. This manual is available within the Part D IPM Module Documentation link located on the left-hand side of the Part D IPM Module landing page.

## Supporting Documentation Submission

Submit all supporting documentation to the HPMS Part D IPM Module during the **12-week submission window**. Submission of documentation through any other avenue is not allowed.

Refer to the HPMS Plan User Guide, located in the HPMS Part D IPM Module, for additional details regarding the submission process.

The following section describes how to name and consolidate supporting documentation. Information regarding what to submit when a certain document cannot be accessed is also provided below.

### ***Document Naming Conventions***

Requirements for supporting documentation differ by type of document.

- The CDF must be labeled with Part D sponsor's contract number, the contract year (year of service), and "CDF" separated by underscores, as shown in the example below.
- Prescription record hardcopies or medication orders must be labeled correctly with the PDE ID followed by "RxRec" separated by underscores, as shown in Figure 27.
  - When ancillary or supplemental documentation is submitted, all documentation must be included together as one document in a PDF file, which must be labeled with the appropriate naming convention. Supplemental documentation may include pages from a medical record or a Physician Attestation form to supplement an unsigned medication order.

**Figure 27: Naming Conventions for Prescription Record Hardcopies or Medication Orders**

Part D IPM Document	Example Naming Convention
Prescription Record Hardcopy/Medication Order	T3513_2024_0019_RxRec
PBM Claim Detail File	T3513_2024_CDF

These naming conventions apply to PDE records processed in LTC and mail/retail pharmacies.

### ***Document Formats***

All prescription record hardcopy/medication order submitted documents must be saved as an image (e.g., PDF, GIF, JPEG, BMP); PDF is the preferred document file format. For the CDF, .xlsx is the required file format.

### ***File Consolidation, Upload, and Verification***


There are two acceptable options for uploading supporting documentation:

- 1) **Single Zip file: all documents for all PDE records consolidated in one Zip file.** All supporting documentation can be zipped within one Zip file. The file should be named after the Part D sponsor's contract number and the contract year (year of service).

As Figure 28 demonstrates, this Part D sponsor has two PDE records sampled for one of its contracts. The Part D sponsor is uploading *five* prescription record hardcopies and *one* CDF

(one prescription record hardcopy for each of the five PDEs, and one CDF containing all the data for all the PDEs).

**Figure 28: Example of Naming Convention and Upload Format for a Single Zip File**



2) **Multiple Zip files; one Zip file for one or multiple PDE records.** If the submission of supporting documentation for PDE records on a rolling basis is preferred, a Zip file for one or multiple PDE records can be uploaded. One or multiple CDFs can be submitted for selected PDEs within a contract (be sure that all the fields for each PDE ID are complete). Each file should be named after the Part D sponsor contract number and contract year (year of service).

Before uploading a file, a radio button must be checked to verify that the documents to be uploaded are accurate to the best of the Part D sponsor's knowledge.

#### ***Ancillary Documentation***

If ancillary documentation is to be submitted to provide more information or context to a supporting document, it must be included in the supporting document image. This means the documents must be scanned at the same time as one PDF or if there are multiple PDFs, they



## Calendar Year 2024

### Part D Improper Payment Measure

should be concatenated into one PDF file. The PDF file must be labeled with the appropriate naming convention as described above.

#### ***Missing Documents***


If a prescription record hardcopy/medication order cannot be obtained, the Part D sponsor must submit a Missing Documentation Form (see Figure 29) in its place. This form allows for an explanation for why the document cannot be accessed and the steps taken to verify that the documentation is not available.

In Section 3 of the form, it is important to specify the source(s) used to verify this information and a detailed explanation of all steps taken. The Missing Documentation Form can be found in the Help Documents folder on the HPMS Part D IPM Module. This document should be named using the same naming convention as the document it replaces. The Module will not accept a Missing Documentation Form in place of the CDF.



Calendar Year 2024  
Part D Improper Payment Measure

Figure 29: Missing Documentation Form



If a Prescription Drug Event (PDE) supporting document (prescription record hardcopy/medication order) is not available for the PDE record, please complete and submit this Missing Documentation form in place of each missing document.

You should complete and upload this form only if the entire PDE supporting document is missing; do not upload this form to explain missing data elements.

Make sure to name this Missing Documentation form according to the naming convention specified below and in the Submission Instructions.

1. Select the missing documentation type, and complete Sections 2 and 3 below:

Documentation Type: Retail / Mail Pharmacy	Documentation Type: Long-Term Care (LTC) Pharmacy	File Naming Convention
<input type="checkbox"/> Prescription Record Hardcopy	<input type="checkbox"/> Medication Order	PDE ID_RxRec

2. Prescription record hard copy/medication order is missing because:

*Document research and actions taken to contact the pharmacy/facility in the comment area below.*

- Pharmacy non-responsive
- Pharmacy sold
- Pharmacy closed
- LTC facility closed
- Pharmacy unable to locate (lost) prescription copy
- Records destroyed by natural disaster (e.g., storm, flood, fire)
- Records seized by law enforcement
- Other (Described in Section 3)

3. Comments and actions taken (use additional page if necessary):

---

---

---

---

*Prescription Record Hardcopy Examples:*

*Example 1:* Consulted internal pharmacy contracting system, pharmacy is inactive. Spoke with Lori at the Maryland State Board of Pharmacy on February 1, 2026, at 4:00 p.m. Confirmed pharmacy was closed on August 1, 2025.

*Example 2:* Spoke with Rich, pharmacy manager on 2/3, 2/5, and 2/9. We faxed the pharmacy a request for records on 2/2 and 2/7. Pharmacy has not responded to our requests for information.



**Calendar Year 2024**  
**Part D Improper Payment Measure**

***CMS Physician Attestation Forms***

Part D sponsors need to submit a separate Physician/Authorized Prescriber CMS Attestation for LTC Medication Order form, along with the original LTC medication order, for each record in which the medication order is not signed by a provider with prescriptive authority and no supplemental documentation is available. Attestation forms are to be used only for medication orders that are not signed by a provider with prescriptive authority or are improperly signed by someone other than an authorized prescriber. The attestation form will allow an authorized prescriber to attest that they approved the LTC medication order in question. Figure 30 is a copy of the CMS-provided attestation form. The form can be found in the Help Documents folder on the HPMS Part D IPM Module.



Calendar Year 2024  
Part D Improper Payment Measure

Figure 30: CMS Physician Attestation Form

**CMS**  
CENTERS FOR MEDICARE & MEDICAID SERVICES

Calendar Year 20XX  
Part D Improper Payment Measure

**Physician/Authorized Prescriber CMS Attestation for  
Long-Term Care (LTC) Medication Order**

**I. Enrollee Information (to be completed by the Part D Sponsor)**

Medicare Identification Number (MBI): \_\_\_\_\_

Last Name: \_\_\_\_\_ First Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_ (mm/dd/yyyy)

Drug Name: \_\_\_\_\_ Drug Strength: \_\_\_\_\_

Date of Service: \_\_\_\_\_

Calendar Year (CY) 20xx Contract ID: \_\_\_\_\_

CY 20xx Part D Sponsor Name: \_\_\_\_\_

**II. Attestation Statement (to be completed by the Physician/Authorized Prescriber)**

I, \_\_\_\_\_, confirm that the prescription drugs listed  
(print or type full name of the physician/authorized prescriber)

in the long-term care medication order dated \_\_\_\_\_ (mm/dd/yyyy) are accurate.  
(medication order written date or date of service)

These medications were prescribed by me in my capacity as the \_\_\_\_\_  
(authorized prescriber credentials, e.g., MD, DO)

when I provided treatment to/diagnosed the Medicare beneficiary mentioned above.

I do hereby attest that this information is true, accurate, and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to administrative, civil, or criminal liability.

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date (mm/dd/yyyy)

## **Verification Checks and Resubmission**

Once a Zip file has been uploaded to the HPMS Part D IPM Module, CMS conducts two checks of the file and its contents to verify the documents. The Verification Checks are as follows:

- File upload check
- Element checks

Notification of successful upload of the file will be evident within minutes of file upload within the HPMS Part D IPM Module. HPMS sends an email regarding the submission status to the Part D sponsor POC(s).

**Refer to the HPMS Plan User Guide for additional information regarding the process status of uploaded files.**

CMS will provide element check results by March 27, 2026, to Part D plan sponsors that have submitted supporting documents on or before the early submission deadline of March 6, 2026. These sponsors will also receive an IFR by March 27, 2026 outlining the preliminary results of their sampled and submitted PDE records.

If these sponsors desire to resubmit supporting documentation based on the results of these checks, they can do so before the final submission deadline of April 17, 2026. **Please submit files as early as possible within the first 6 weeks of the submission period window to allow ample time to receive the results of element checks, and to provide time to update any required files to ensure complete and valid documentation and resubmit before the submission deadline.**

CMS and/or its contractor may contact Part D sponsors during or after the submission period to request clarification regarding submitted files. At this time, CMS may request resubmission of supporting documentation.

**Refer to the HPMS Plan User Guide, available on the Part D IPM Module, for additional details regarding the resubmission of supporting documentation.**

When resubmitting a supporting document that was previously missing or deemed invalid, only resubmit the corrected/valid document. **Do not resubmit other documents that are not missing or invalid.** Also, if asked to resubmit a supporting document because it is missing data elements, the resubmitted file must contain both the newly requested data elements **and** the data elements that were included on the previous document. **Do not submit a document with just the new data elements.**

Furthermore, if you would like to explain why data elements are missing from a document, you can do so on the HPMS Part D IPM Module Discussion Board. **Do not submit a Missing Documentation form or some other document describing why the data elements are missing. Do not use PHI or PII when communicating about a PDE record via the Discussion Board.**

All files submitted by the final submission deadline, whether deemed incomplete or any other issue, will be reviewed during the Part D IPM process.

## **Best Practices**

Part D sponsors must carefully adhere to guidelines regarding required information to ensure their PDE submissions are complete and contain the best possible documentation. CMS recommends the following actions and best practices to help improve adherence to submission guidelines and minimize burden when submitting through the submission window:

- Take note that the final submission deadline of **Friday, April 17, 2026**, is the last date on which you can submit supporting documentation.
- Thoroughly review the recorded learning series available in HPMS, specifically Module 3, pertaining to the documentation submission process.
- Submit both the CDF and prescription record hardcopy/long-term care medication order as early as possible.
  - Confirm the prescription record hardcopy/long-term care medication order pertains to the sampled PDE and the associated beneficiary.
  - Diligently review the CDF to ensure alignment of data with the sampled PDE.
- Compare your supporting documentation against the PDE Record Identifier spreadsheet provided to minimize the need for resubmission.
- Ensure all documentation for all your PDE records are consolidated in one Zip package. The package must contain the requested documentation for the Part D IPM. Please confirm you are not submitting documentation meant for another audit.
- Verify that you are using the correct naming conventions while uploading documentation.
- Recognize that acceptable documentation comes in various forms. Refer to this document for a detailed list of required elements for each supporting document, along with the examples provided of both acceptable and unacceptable documents.
- For necessary attestations, use only the CMS-provided Physician/Authorized Prescriber Attestation for Long-Term Care (LTC) Medication Orders form. (Alternative forms are NOT accepted.)
- Use the HPMS Part D IPM Module Discussion Board to seek clarifications if you are uncertain about submission requirements.
- Delegate the identification of required data elements on the prescription record hardcopy/LTC medication order to personnel familiar with prescription processes. This business process improves key generation and mapping outcomes.
- Seek approval for prepared documents from your Medicare Compliance Officer or other experienced personnel, such as a Pharmacy Director. They should validate that the documents most accurately represent and substantiate the final PDE record.
- Involve knowledgeable personnel from your plan who have information systems access to collect and submit supporting documentation. Ensure they have access to accurate data sources representing the claim data contributing to or forming the Part D sponsor's PDE submission before uploading to HPMS.

- Review all prescription record hardcopies and/or medication orders subject to PDE submission and confirm prior to uploading documentation that the documents are signed by licensed providers.
- Provide explanatory comments or documents when the beneficiary named on the prescription record hardcopy/medication order is not the same as the beneficiary named on the CDF. For example, the beneficiary may answer to a different name (nickname) rather than their given name. As such, the CDF shows the beneficiary's given name while the prescription record hardcopy may refer to the beneficiary's non-given name.
- Submit an explanation/additional information if a pharmacy sends prescription record hardcopy documentation that fails to support the PDE. Common examples include:
  - Prescription record hardcopies for a drug strength that is not commercially available. Part D sponsors submitted an explanation of how the beneficiary received the dose prescribed (e.g., two prescriptions of varying strengths were dispensed, a larger quantity of a lower strength was dispensed) and how this was reflected on the PDE.
  - Prescription record hardcopies for a drug that fails to match the drug listed on the PDE. Part D sponsors submitted an explanation indicating why the prescribed drug misaligns to the PDE (e.g., the pharmacy contacted the physician to change the drug to comply with the Part D sponsor's formulary, the original drug prescribed was unavailable, the original drug prescribed was changed due to interactions with other therapy the beneficiary was receiving).
  - Prescription record hardcopies for a quantity that fails to match the quantity listed on the PDE. Part D sponsors submitted an explanation indicating why the prescribed quantity misaligns to the quantity on the PDE (e.g., a lesser quantity was dispensed due to a Part D sponsor's limitation on days' supply available to a beneficiary at retail or by beneficiary request).
- Provide details or an explanation for any PDE that has already been adjusted or corrected in the DDPS.

## Contact Information

For any questions or concerns regarding Part D IPM activity, use the email addresses below. Initial responses will be provided within 1 business day; however, resolution of issues may require additional time.

## Policy Questions

Questions regarding CMS policies related to the Part D IPM process should be sent to [PartD\\_IPM@cms.hhs.gov](mailto:PartD_IPM@cms.hhs.gov).

Please include "Part D IPM 2024" in the subject line.

## Part D IPM Submission Process Questions

Questions posted on the HPMS Part D IPM Module Discussion Board, available at [hpms.cms.gov](http://hpms.cms.gov), will be answered by the relevant party depending on the subject matter (i.e.,



## Calendar Year 2024

### Part D Improper Payment Measure

PDE ID-specific questions and submission questions). Please note that only authorized users will be able to access and view the Discussion Board(s) for their authorized contract(s). **Do not use PHI or PII when communicating about a PDE record via email or the Discussion Board. Please use the PDE ID to identify the PDE instead.**

#### **HPMS Help Desk**

Send technical questions concerning HPMS, the Part D IPM Module, and the supporting documentation upload process to [hpms@cms.hhs.gov](mailto:hpms@cms.hhs.gov).

#### **CMS Meeting Request**

To request a meeting with CMS, email [PartD\\_IPM@cms.hhs.gov](mailto:PartD_IPM@cms.hhs.gov). Please include: "Contract Number – Meeting Request" in the subject line and details about your meeting request.



Calendar Year 2024  
Part D Improper Payment Measure

## Appendix A. CMS Policy Regarding Adjusted Claims

The deadline for submission of PDE data for the CY 2024 Part D Payment Reconciliation was June 27, 2025. The PDE records that CMS sampled for the current CY 2023 Part D IPM process were submitted on or before this date. The CY 2024 Part D IPM process validates the PDE record that the Part D sponsor determined was the final PDE record for purposes of the CY 2024 Part D Payment Reconciliation.

In the situation where the sponsor subsequently adjusted the sampled “recon PDE” (adjustment made **AFTER** June 27, 2025), the requirement is as follows:

- The sponsor must submit documentation that **aligns to the PDE submitted to CMS as the “RECON PDE.”** This version should align to the PDE identifiers and match the specified fields in the sampled “recon PDE”; and
- The sponsor must submit additional documentation indicating that the sampled PDE record was adjusted following reconciliation.
  - Please be sure this additional documentation is linked to an adjusted PDE *if* it supports the intended field(s) in the “recon PDE.” See the earlier section in these Submission Instructions for additional information on submitting optional or supplemental documentation.
- If the sponsor cannot locate documentation for the sampled “recon PDE,” upload a Missing Documentation form in place of each missing document. This form and instructions for completion and submission can be found in the Help Documents library on the HPMS Part D IPM Module.
- Data in the CDF must match the PDE record submitted for reconciliation in the 11 fields provided as PDE identifiers (the PDE\_ID Number and the 10 unique identifiers) associated with the PDE being reviewed and the Part D sponsor Contract ID Number.



**Calendar Year 2024**  
**Part D Improper Payment Measure**

## **Appendix B. PDE Layout**

The [PDE Inbound Layout File](#), effective January 1, 2024, can be found on the CMS Customer Service and Support Center (CSSC) website.

**END OF DOCUMENT**